ReShape Lifesciences Inc. ETRM
No live quote for ETRM yet.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.50
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.29 | -0.29 – -0.29 | -34.30 | +99.2% | 310.00K | +4.4% | 1 |
| Next quarter | -0.16 | -0.16 – -0.16 | -11.90 | +98.7% | 910.00K | 0.0% | 1 |
| Current year | -1.40 | -1.40 – -1.40 | 0.00 | 0.0% | 1.35M | 0.0% | 1 |
| Next year | -0.64 | -0.64 – -0.64 | -1.40 | +54.3% | 6.49M | +380.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 2, 2017 | Ladenburg Thalmann | Initiated | — | Buy |
| Jun 8, 2016 | Roth Capital | Downgrade | — | Neutral |
| Oct 14, 2013 | Lake Street | Initiated | — | Buy |
| Dec 19, 2012 | Roth Capital | Initiated | — | Buy |